Seres Therapeutics, Inc. (MCRB) is a pioneering microbiome therapeutic platform company based in Cambridge, Massachusetts, focused on innovating bacterial consortia to effectively engage with host biology for the treatment of various diseases. With a robust pipeline targeting conditions such as Clostridioides difficile infection and inflammatory bowel disease, Seres leverages its expertise in microbiome science to develop transformative therapies aimed at restoring microbiome balance and improving patient outcomes. The company's commitment to advancing the understanding of microbiome interactions positions it as a leader in the evolving field of microbiome therapeutics.